| 2025-02-11 |
复牌提示：
2025-02-11 08:13:44 停牌，复牌日期 2025-02-12 00:00:01
|
| 2025-02-07 |
详情>>
内部人交易：
Silverstein Christine Berni等共交易18笔
|
| 2024-12-30 |
详情>>
股本变动：
变动后总股本5521.85万股
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.73美元,归母净利润-9872.2万美元,同比去年增长0.92%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-1.31美元,归母净利润-7449.7万美元,同比去年增长-11.75%
|
| 2024-08-13 |
财报披露：
美东时间 2024-08-13 盘前发布财报
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.68美元,归母净利润-3866.9万美元,同比去年增长-11.34%
|
| 2024-04-04 |
股东大会：
将于2024-05-22召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to our Board of Directors (our “Board”), each to serve until our 2027 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified (“Proposal 1”).
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Proposal 2”).
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Proxy Statement (“Proposal 3”).
4.To approve the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan (“Proposal 4”).
5.To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益-2.63美元,归母净利润-1.41亿美元,同比去年增长-613.59%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.89美元,归母净利润-9963.6万美元,同比去年增长-803.64%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-1.28美元,归母净利润-6666.4万美元,同比去年增长-13.39%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.67美元,归母净利润-3473万美元,同比去年增长-79.38%
|
| 2023-04-11 |
股东大会：
将于2023-05-24召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to our Board of Directors (our “Board”), each to serve until our 2026 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified (“Proposal 1”).
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 (“Proposal 2”).
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Proxy Statement (“Proposal 3”).
4.To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2023-03-09 |
详情>>
业绩披露：
2022年年报每股收益-0.51美元,归母净利润-1981.6万美元,同比去年增长79.94%
|
| 2022-11-07 |
详情>>
业绩披露：
2022年三季报(累计)每股收益0.38美元,归母净利润1416.00万美元,同比去年增长120.09%
|
| 2022-08-11 |
详情>>
业绩披露：
2022年中报每股收益-1.59美元,归母净利润-5879.4万美元,同比去年增长-15.36%
|
| 2022-04-11 |
股东大会：
将于2022-05-25召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors to our Board of Directors (our “Board”), each to serve until our 2025 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified (“Proposal 1”).
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022 (“Proposal 2”).
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Proxy Statement (“Proposal 3”).
4.To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-14 |
股东大会：
将于2021-05-26召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to our Board of Directors (our “Board”), each to serve until our 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified (“Proposal 1”).
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021 (“Proposal 2”).
3.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Proxy Statement (“Proposal 3”).
4.To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-09-23 |
详情>>
拆分方案：
每4.0000合并分成1.0000股
|
| 2020-04-27 |
股东大会：
将于2020-05-27召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors to the Company’s Board of Directors (the “Board”), each to serve until the Company’s 2023 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified (“Proposal 1”).
2.To approve an amendment to the Company’s 2014 Equity Incentive Plan, as amended (the “2014 Plan”), to (a) increase, on an annual basis on January 1 of each year, the maximum number of shares of the Company’s common stock available for issuance under the 2014 Plan and the number of shares of the Company’s common stock that may be issued under the 2014 Plan as incentive stock options by a number equal to the least of (i) 10,000,000 shares (previously 5,000,000) of the Company’s common stock, (ii) an amount equal to 4% (unchanged) of the total number of shares of the Company’s capital stock outstanding on such date, calculated on a common-equivalent basis, and (iii) an amount determined by the Board, and (b) eliminate the provision setting a maximum aggregate number of shares of the Company’s common stock that may be subject to grants made under the 2014 Plan to any individual during a calendar year (“Proposal 2”).
3.To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the number of authorized shares of the Company’s common stock from 150,000,000 shares to 300,000,000 shares, with such authorized share increase to be effected at such time and date, if at all, as determined by the Board in its sole discretion (“Proposal 3”).
4.To approve an amendment to the Certificate of Incorporation to decrease the number of authorized shares of the Company’s common stock from 300,000,000 shares to 150,000,000 shares, with such authorized share decrease to be effected if (a) the Company’s stockholders approve the authorized share increase set forth in Proposal 3 and such authorized share increase has previously been effected and (b) the previously approved reverse stock split of the Company’s common stock at a ratio of 1-for-4 has previously been effected (“Proposal 4”).
5.To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 (“Proposal 5”).
6.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying proxy statement (“Proposal 6”).
7.To recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of the Company’s named executive officers (“Proposal 7”).
8.To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-03-02 |
股东大会：
将于2020-03-31召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 150,000,000 shares (the “Authorized Shares Proposal”);
2.To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-4, with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s Board of Directors (the “Board”) in its sole discretion (the “Reverse Stock Split Proposal”);
3.To approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes to approve the Authorized Shares Proposal or the Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2019-03-25 |
股东大会：
将于2019-05-07召开股东大会
会议内容 ▼▲
- 1.The election of three Class II director nominees named in the accompanying Proxy Statement;
2.Approve an amendment to our 2014 Equity Incentive Plan (the “2014 Plan”) increasing, on an annual basis, the maximum number of shares of the Company’s common stock available for issuance under the 2014 Plan by a number equal to the lesser of (i) 5,000,000 shares (previously 2,000,000 shares) of the Company’s common stock, (ii) an amount equal to 4% (previously 5%)of the total number of shares of the Company’s common stock outstanding on such date, calculated on a common-equivalent basis, or (iii) an amount determined by the Board, each of which may be granted as incentive stock options, and increasing the maximum aggregate number of shares of the Company’s common stock that shall be subject to Grants (as defined in the 2014 Plan) made under the 2014 Plan to any individual during any calendar year to 2,000,000 shares (previously 1,000,000);
3.Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.Transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-03-07 |
股东大会：
将于2018-04-19召开股东大会
会议内容 ▼▲
- 1.The election of two Class I director nominees named in the accompanying Proxy Statement;
2.Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.Transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-03-16 |
股东大会：
将于2017-05-11召开股东大会
会议内容 ▼▲
- 1.The election of two Class III director nominees named in the accompanying Proxy Statement;
2.Approve an amendment to our 2014 Equity Incentive Plan (the “2014 Plan”) increasing the maximum number of shares of common stock available for issuance under the 2014 Plan from 2,824,149 (which includes annual increases on January 1 of 2017, 2016 and 2015) to 4,158,164, and increasing the number of shares of common stock available for issuance under the 2014 Plan pursuant to future annual increases on January 1 of each year, commencing January 1, 2018, from the lesser of 1,120,000 common shares or 4% of the total number of shares of the Company’s capital stock calculated on a common-equivalent basis and outstanding on that date, or such lesser number of shares as the Company’s board of directors may determine, to the lesser of 2,000,000 common shares or 5% of the total number of shares outstanding on that date shares of the Company’s capital stock calculated on a common-equivalent basis and outstanding on that date, or such lesser number of shares as the Company’s board of directors may determine.
3.Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
4.Transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2016-03-07 |
股东大会：
将于2016-04-19召开股东大会
会议内容 ▼▲
- 1.The election of two Class II director nominees named in the accompanying Proxy Statement;
2.Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.Transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2015-03-17 |
股东大会：
将于2015-04-21召开股东大会
会议内容 ▼▲
- 1.The election of two Class I director nominees named in the accompanying Proxy Statement;
2.Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
3.Transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
|